People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vavotar Life Sciences LLC | — | Other Health Care | Series C | $156.0M | $228.6M | 2016 |
| CoRegen, Inc. | — | Biotechnology | Series C | $134.3M | $72.6M | 2025 |
| DemeRx, Inc. | — | Pharmaceuticals | Series A | $28.7M | $9.0M | 2012 |
| Rion LLC | — | Biotechnology | Series B | $25.4M | $693.5M | 2017 |
| Polarityte, Inc. | — | Biotechnology | Series B | $24.0M | $69.4M | 2017 |
| H-Cyte, Inc. | — | Other Health Care | Series A | $14.6M | $58.1M | 2016 |
| SmartPharm Therapeutics, Inc. | — | Pharma | Series A | $10.5M | $326.0M | 2018 |
| Mimedx Group, Inc. | — | Biotechnology | Seed | $8.2M | $177.6M | 2009 |
| AperiSys, Inc. | — | Other Health Care | Seed | $6.2M | $16.9M | 2015 |
| Celnyx, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2009 |
| Genomic Cancer Institute, Inc. | — | Other Health Care | Seed | $1.5M | $2.8M | — |
Steve Gorlin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve Gorlin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles Farrahar | 4 | 4 |
| Parker H. Petit | 3 | 5 |
| John C. Thomas, Jr. | 3 | 5 |
| Charles E. Koob | 2 | 3 |
| John Thomas, Jr. | 2 | 2 |
| Jon Mogford | 2 | 2 |
| Bruce L. Hack | 2 | 2 |
| Matthew Miller | 1 | 15 |
| John Thomas | 1 | 10 |
| MICHAEL CALLAHAN | 1 | 7 |
| John Preston | 1 | 7 |
| Barry Honig | 1 | 6 |
| MICHAEL BRAUSER | 1 | 6 |
| William E. Horne | 1 | 4 |
| MATTHEW J. MILLER | 1 | 4 |
| Peter Cohen | 1 | 3 |
| Andrew Danielsen | 1 | 3 |
| Steve J. Gorlin | 1 | 3 |
| John Stetson | 1 | 3 |
| Larry Papasan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.